100 related articles for article (PubMed ID: 3664501)
1. Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.
McGuire JJ; Sobrero AF; Hynes JB; Bertino JR
Cancer Res; 1987 Nov; 47(22):5975-81. PubMed ID: 3664501
[TBL] [Abstract][Full Text] [Related]
2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
3. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
Jackman AL; Alison DL; Calvert AH; Harrap KR
Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
[TBL] [Abstract][Full Text] [Related]
4. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs.
Schultz RM; Chen VJ; Bewley JR; Roberts EF; Shih C; Dempsey JA
Semin Oncol; 1999 Apr; 26(2 Suppl 6):68-73. PubMed ID: 10598558
[TBL] [Abstract][Full Text] [Related]
5. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
6. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
[TBL] [Abstract][Full Text] [Related]
7. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
[TBL] [Abstract][Full Text] [Related]
8. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
9. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
10. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation.
Jackman AL; Kimbell R; Brown M; Brunton L; Bisset GM; Bavetsias V; Marsham P; Hughes LR; Boyle FT
Anticancer Drug Des; 1995 Oct; 10(7):573-89. PubMed ID: 7495480
[TBL] [Abstract][Full Text] [Related]
12. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
14. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and potent antifolate activity and cytotoxicity of B-ring deaza analogues of the nonpolyglutamatable dihydrofolate reductase inhibitor Nalpha-(4-amino-4-deoxypteroyl)-Ndelta-hemiphthaloyl- L-ornithine (PT523).
Rosowsky A; Wright JE; Vaidya CM; Bader H; Forsch RA; Mota CE; Pardo J; Chen CS; Chen YN
J Med Chem; 1998 Dec; 41(26):5310-9. PubMed ID: 9857098
[TBL] [Abstract][Full Text] [Related]
16. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase.
Hanlon MH; Ferone R
Cancer Res; 1996 Jul; 56(14):3301-6. PubMed ID: 8764125
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of lipophilic quinazoline inhibitors of thymidylate synthase.
Jones TR; Varney MD; Webber SE; Lewis KK; Marzoni GP; Palmer CL; Kathardekar V; Welsh KM; Webber S; Matthews DA; Appelt K; Smith WW; Janson CA; Villafranca JE; Bacquet RJ; Howland EF; Booth CL; Herrmann SM; Ward RW; White J; Moomaw EW; Bartlett CA; Morse CA
J Med Chem; 1996 Feb; 39(4):904-17. PubMed ID: 8632414
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells.
Smith SG; Lehman NL; Moran RG
Cancer Res; 1993 Dec; 53(23):5697-706. PubMed ID: 8242626
[TBL] [Abstract][Full Text] [Related]
19. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
[TBL] [Abstract][Full Text] [Related]
20. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
